Evidence map›Paper›PMID 27539728›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Novel dual-mode nanobubbles as potential targeted contrast agents for female tumors exploration.

Hengli Yang, Tian Zhou, Wenbin Cai, Xiaomin Yi, Xi Liu, Yixiao Wang, Li Zhang, Yunyou Duan

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Nanosized Contrast Agents in Ultrasound Molecular Imaging.Frontiers in bioengineering and biotechnology · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hengli YangDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China.ORCID http://orcid.org/0000-0002-4938-3319
Tian ZhouDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China.
Wenbin CaiDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China.
Xiaomin YiDepartment of Urology, PLA 105 Hospital, Hefei, China.
Xi LiuDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China.
Yixiao WangDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China.
Li ZhangDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China. lizhyhl@hotmail.com.
Yunyou DuanDepartment of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China. duanyy@fmmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to prepare tumor-specific dual-mode nanobubbles as both ultrasound contrast agents (UCAs) and near-infrared fluorescence (NIRF) imaging agents for female tumors. Recent studies have demonstrated the conjugation of anti-tumor ligands on the surface of nanobubbles for use as molecule-targeting ultrasound contrast agents for tumor visualization. However, this complicated procedure has also posed a challenge to nanobubble stability. Thus, in the present study, we combined the fluorescent dye, NIRF IR-780 iodide, which has lipid solubility and tumor-targeting characteristics, with the phospholipid film of nanobubbles that we constructed. We then characterized the physical features of the IR-780-nanobubbles, observed their tumor-targeting capacity in multiple female tumor cell types in vitro, and verified their capability for use in tumor-specific ultrasound contrast imaging and NIRF imaging in vivo. The results showed that the new IR-780-nanobubbles had a uniform nano-size (442.5 ± 48.6 nm) and stability and that they were safe and effective at NIRF imaging and ultrasound imaging in vitro. The IR-780-nanobubbles were found to automatically accumulate on different female tumor cells in vitro with a considerable targeting rate (close to 40 %) but did not accumulate on cardiac muscle cells used as a negative control. Importantly, the IR-780-nanobubbles can detect female tumors precisely via dual-mode imaging in vivo. In conclusion, the new dual-mode IR-780-nanobubbles are stable and have potential advantages in non-invasive tumor-specific detection for female tumors via contrast-enhanced ultrasound and NIRF imaging.

Indexed as

Contrast MediaIndolesAnimalsApoptosisBreast NeoplasmsCell ProliferationFemaleFlow CytometryHumansMiceMice, Inbred BALB CMice, NudeNanoparticlesTumor Cells, CulturedUltrasonographyXenograft Model Antitumor Assays2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindoliumContrast MediaIndolesDual-modeFemale tumorsIR-780-nanobubblesTumor-specific

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.